As knowledge of AD progression improves, the field has recognized the need to diversify the pipeline, broaden strategies and approaches to therapies, as well as delivery mechanisms. A better understanding of the earliest biological processes of AD/dementia would help inform drug target selection. Currently, there are a number of programs exploring these alternate avenues. This meeting will allow experts in the field to provide perspectives and experiences that can help elucidate what the pipeline looks like today and what avenues are most promising to forward for the development of new therapies, across the stages of Alzheimer's disease.

The focus will be on Active Immunotherapies and Alternative Therapeutic Modalities.  This topic will include active vaccines, antisense oligomers, cell based therapies, and highlight new clinical developments that utilize these modalities.